Toxicities and surgery completion rates in patients underwent treatments with FDA-approved neoadjuvant, adjuvant and perioperative regimens

Trial (NCT#)Adverse events (ICI vs. placebo)Patients who completed surgery (ICI vs. placebo)
TotalNeoadjuvant AdjuvantICI mediated
IMpower010 (NCT02486718)93% vs. 71%N/A93% vs. 71%52% vs. 9%100% vs. 100%
KEYNOTE 091/PEARLS (NCT02504372)96% vs. 91%N/A96% vs. 91%39% vs. 13%100% vs. 100%
CheckMate 816 (NCT02998528)92.6% vs. 97.2%92.6% vs. 97.2%N/A20% vs. 1%83.2% vs. 75.4%
KEYNOTE 671 (NCT03425643)96.7% vs. 95%95.7% vs. 93.7% (neoadjuvant + surgery phase)54.5% vs. 31.8%25.3% vs. 10.5%82.1% vs. 79.4%
AEGEAN (NCT03800134)96.5% vs. 94.7%91.0% vs. 89.2%Unknown23.7% vs. 9.3%77.6% vs. 76.7%
CheckMate 77T (NCT04025879)97.4% vs. 97.8%94.7% vs. 96.1%87.3% vs. 79.6%35.2% vs. 7.8%77.7% vs. 76.7%

FDA: Food and Drug Administration; ICI: immune checkpoint inhibitors